Balyasny Asset Management’s Synergy Pharmaceuticals, Inc Common Stock SGYP Stock Holding History

Balyasny Asset Management’s Portfolio SGYP Stock Details SGYP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q3	–	Sell	-688,813	Closed	-$1.2M	–	2245
2018 Q2	$1.2M	Sell	688,813 -58,687	-8%	-$101K	0.01%	1076
2018 Q1	$1.37M	Sell	747,500 -927,500	-55%	-$1.96M	0.01%	1108
2017 Q4	$3.73M	Buy	1,675,000 +291,600	+21%	+$725K	0.01%	950
2017 Q3	$4.01M	Buy	+1,383,400	New	+$4.72M	0.02%	788
2016 Q3	–	Sell	-62,988	Closed	-$239K	–	1402
2016 Q2	$239K	Sell	62,988 -11,652	-16%	-$39.5K	﹤0.01%	978
2016 Q1	$206K	Sell	74,640 -35,730	-32%	-$129K	﹤0.01%	1122
2015 Q4	$626K	Buy	110,370 +68,470	+163%	+$417K	﹤0.01%	786
2015 Q3	$222K	Buy	41,900 +22,450	+115%	+$174K	﹤0.01%	992
2015 Q2	$161K	Buy	+19,450	New	+$94.3K	﹤0.01%	1037

Other funds holding SGYP

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Hikari Power Tokyo, Japan $855M AUM 14.24% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

HighTower Advisors Chicago, Illinois $104B AUM 28.3% 1-Year Est. Return

Balyasny Asset Management's SGYP Position: Q3 2018 in Review

Balyasny Asset Management sold out of Synergy Pharmaceuticals, Inc Common Stock (SGYP) in Q3 2018, closing a stake of 688,813 shares — an estimated $1.2M sold.

Balyasny Asset Management first reported a position in SGYP in Q2 2015 and held it in 9 quarters. The position peaked at $4.01M in Q3 2017. 133 funds tracked by Wall St. Rank hold SGYP as of Q3 2018.

Balyasny Asset Management reported no remaining Synergy Pharmaceuticals, Inc Common Stock position as of Q3 2018 after selling out during the quarter.
Balyasny Asset Management sold 688,813 Synergy Pharmaceuticals, Inc Common Stock shares in Q3 2018, an estimated $1.2M.
Balyasny Asset Management first reported a position in Synergy Pharmaceuticals, Inc Common Stock in Q2 2015 and held it in 9 quarters.
Balyasny Asset Management's Synergy Pharmaceuticals, Inc Common Stock position peaked at $4.01M in Q3 2017.
133 funds tracked by Wall St. Rank held Synergy Pharmaceuticals, Inc Common Stock as of Q3 2018.

Based on Balyasny Asset Management's 13F filing for Q3 2018, filed 14 Nov 2018.